Spots Global Cancer Trial Database for acute myelogenous leukemia (aml)
Every month we try and update this database with for acute myelogenous leukemia (aml) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia | NCT00528983 | Myelodysplastic... Chronic Myelomo... Acute Myelogeno... | Subcutaneous (S... Oral Azacitidin... Oral Azacitidin... | 18 Years - | Celgene | |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | NCT01050764 | Leukemia, Acute Chronic Myeloge... Myelodysplastic... Non-Hodgkin Lym... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Regulatory T-ce... Conventional T-... Melphalan Thiotepa Fludarabine Anti-thymocyte ... CliniMACS CD34 ... | - 60 Years | Stanford University | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders | NCT00596999 | Hematologic Mal... | UCB and HPDSC | - 55 Years | Celgene | |
| Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant | NCT00088543 | Acute Myelogeno... Acute Lymphocyt... Graft vs. Host ... | Thymoglobulin [... Thymoglobulin [... | 18 Years - 55 Years | Sanofi | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | NCT02989844 | Acute Myelogeno... Myelodysplastic... | N-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | NCT03412292 | Acute Myelogeno... | MAX-40279 | 18 Years - | Maxinovel Pty., Ltd. | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | NCT00088231 | Acute Myelogeno... Agnogenic Myelo... Chronic Myeloge... | Imatinib Mesyla... PTK 787 (vatala... | 15 Years - | M.D. Anderson Cancer Center | |
| A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | NCT03600909 | Fanconi Anemia Myelodysplastic... Acute Myelogeno... | Busulfan Fludarabine Cyclophosphamid... Anti-Thymocyte ... The CliniMACS d... G-CSF | 1 Month - | Memorial Sloan Kettering Cancer Center | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) | NCT00179764 | Tumors Malignant Melan... Hematological M... Myelogenous Leu... Leukemia, Lymph... | Immunoablative ... Busulfan pharma... Central Nervous... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT01440374 | Thrombocytopaen... | eltrombopag placebo | 18 Years - 110 Years | Novartis | |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | NCT02989844 | Acute Myelogeno... Myelodysplastic... | N-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) | NCT01451437 | Acute Myelogeno... | MK-8242 | 18 Years - | Merck Sharp & Dohme LLC | |
| Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | NCT01527838 | Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Single FT1050 t... | 18 Years - 65 Years | Fate Therapeutics | |
| MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | NCT00374296 | Myelogenous Leu... Myelodysplastic... | MGCD0103 | 18 Years - | Mirati Therapeutics Inc. | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | NCT03412292 | Acute Myelogeno... | MAX-40279 | 18 Years - | Maxinovel Pty., Ltd. | |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant | NCT00088543 | Acute Myelogeno... Acute Lymphocyt... Graft vs. Host ... | Thymoglobulin [... Thymoglobulin [... | 18 Years - 55 Years | Sanofi | |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | NCT00943553 | Acute Myelogeno... | decitabine Indu... Induction Chemo... | 1 Year - 16 Years | Eisai Inc. | |
| Red Cell Transfusion Goals in Patients With Acute Leukemias | NCT02086773 | Acute Lymphobla... Acute Lymphocyt... Acute Myelogeno... Acute Promyeloc... | Red blood cell ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | NCT01885897 | Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Lymphoma Myeloma Chronic Lymphoc... Chronic Myeloge... | ALT-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer | NCT02240537 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Smoldering Mult... | Sargramostim BB-MPI-03 Montanide | 18 Years - | Benovus Bio, Inc. | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | NCT00433745 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1 Peptide Vac... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders | NCT00596999 | Hematologic Mal... | UCB and HPDSC | - 55 Years | Celgene | |
| Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | NCT01265199 | Acute Myelogeno... | AT-406 in combi... | 18 Years - 74 Years | Ascenta Therapeutics | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | NCT02061800 | Chronic Myeloid... Acute Myelogeno... Myelodysplastic... Juvenile Myelom... Acute Lymphobla... Lymphoma (Hodgk... | CliniMACS CD34+... Thiotepa Cyclophosphamid... Alemtuzumab Tacrolimus Melphalan Busulfan Fludarabine Methylprednisol... | - 22 Years | Columbia University | |
| Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) | NCT01451437 | Acute Myelogeno... | MK-8242 | 18 Years - | Merck Sharp & Dohme LLC | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia | NCT00001623 | Graft vs Host D... Hematologic Neo... Leukemia Multiple Myelom... Myelodysplastic... | Allogeneic Bone... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | NCT01995578 | Myelodysplastic... Acute Myelogeno... | low dose 5'-aza... | 1 Year - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | NCT03260101 | Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom... | non intervation... | 18 Years - 70 Years | Cellect Biotechnology | |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | NCT02730299 | Hematological M... Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Lymphoma Acute Leukemia | NiCord® (omidub... Cord Blood Unit | 12 Years - 65 Years | Gamida Cell ltd | |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | NCT02989844 | Acute Myelogeno... Myelodysplastic... | N-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Red Cell Transfusion Goals in Patients With Acute Leukemias | NCT02086773 | Acute Lymphobla... Acute Lymphocyt... Acute Myelogeno... Acute Promyeloc... | Red blood cell ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | NCT00672152 | Acute Myelogeno... Chronic Myeloge... Acute Lymphobla... Myelodysplastic... B Cell Malignan... | WT1 derived pep... | 18 Years - | Duke University | |
| MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | NCT00374296 | Myelogenous Leu... Myelodysplastic... | MGCD0103 | 18 Years - | Mirati Therapeutics Inc. | |
| Unrelated Umbilical Cord Blood (UBC)Transplantation | NCT01768845 | Chronic Myeloge... Acute Myelogeno... Myelodysplastic... Multiple Myelom... Hodgkin Lymphom... Non-Hodgkin Lym... Chronic Lymphoc... Acute Lymphocyt... Severe Aplastic... | umbilical cord ... | 16 Years - 70 Years | West Virginia University | |
| Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant | NCT00088543 | Acute Myelogeno... Acute Lymphocyt... Graft vs. Host ... | Thymoglobulin [... Thymoglobulin [... | 18 Years - 55 Years | Sanofi | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
